BioNTech, MediLink to resume trial enrollment for HER3 antibody-drug conjugate after FDA pause

Lei Lei Wu

News Reporter

Amber Tong

The FDA on Thursday lifted a partial clinical hold on an early-stage study of a HER3-targeting antibody-drug conjugate that BioNTech is developing with China-based MediLink …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioNTech, MediLink to resume trial enrollment for HER3 antibody-drug conjugate after FDA pause

Lei Lei Wu

News Reporter

Amber Tong

Sign up to read this article for free.

AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Lexicon plots Phase 3 trial for diabetic pain drug despite mid-stage flop

Trump blog: Senior HHS comms official resigns within weeks of being sworn in

At least seven drugmakers say they will participate in round two of IRA negotiations

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

BioN­Tech, MediLink to re­sume tri­al en­roll­ment for HER3 an­ti­body-drug con­ju­gate af­ter FDA pause

News Reporter

Sign up to read this article for free.

BioNTech, MediLink to resume trial enrollment for HER3 antibody-drug conjugate after FDA pause